CPHI
AMEX · Pharmaceuticals
China Pharma Holdings Inc
$0.57
+0.04 (+7.53%)
Financial Highlights (FY 2026)
Revenue
38.64M
Net Income
-29,719,377
Gross Margin
-3.2%
Profit Margin
-76.9%
Rev Growth
-20.0%
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -3.2% | -3.2% | 44.6% | 44.6% |
| Operating Margin | -78.2% | -70.3% | 15.6% | 17.1% |
| Profit Margin | -76.9% | -73.1% | 12.8% | 15.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 38.64M | 48.32M | 1.71M | 1.69M |
| Gross Profit | -1,228,675 | -1,536,419 | 763.3K | 752.6K |
| Operating Income | -30,199,140 | -33,986,777 | 266.9K | 288.3K |
| Net Income | -29,719,377 | -33,446,841 | 218.9K | 263.0K |
| Gross Margin | -3.2% | -3.2% | 44.6% | 44.6% |
| Operating Margin | -78.2% | -70.3% | 15.6% | 17.1% |
| Profit Margin | -76.9% | -73.1% | 12.8% | 15.6% |
| Rev Growth | -20.0% | -20.0% | -8.6% | -6.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.49M | 1.49M | 1.64M | 1.66M |
| Total Equity | 9.91M | 9.91M | 2.45M | 2.52M |
| D/E Ratio | 0.15 | 0.15 | 0.67 | 0.66 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -22,257,524 | -26,440,725 | 383.8K | 387.9K |
| Free Cash Flow | — | — | 127.8K | 154.0K |